The FDA accepted two applications from Swiss drugmaker Sandoz for generic versions of Eli Lilly’s tirzepatide medications, Mounjaro and Zepbound. These treatments currently lead the rapidly expanding market for type-2 diabetes and weight management.
Eli Lilly holds U.S. patents on tirzepatide that are not expected to expire until 2036. Sandoz aims to be among the first companies to offer generic versions once the market forms. The FDA typically completes standard drug application reviews within a 10-month timeline.
Investors in healthcare ETFs like IYH and VHT are monitoring the development for its impact on Eli Lilly’s long-term valuation. Early generic challenges can shift revenue projections for brand-name pharmaceutical manufacturers years in advance. This move underscores the strategic role of the generics industry within the broader healthcare sector.